We may create a catch-22 so that only people who are unlikely to need health insurance can afford it. ... Genetic risk testing is important because it exposes the logic of a system that provides access to health insurance to those least likely to need it. 1 T he fear of generic discriminarion 2 in the health in-· surance contexrl cannot be underestimated. Some have argued that individuals who might otherwise choose genetic testing will decline it based on their fear that they or their family members will not be able to obtain or maintain health insurance coverage.~ As a result, the future of research on the benefits and risks of testing for genetic conditions, including susceptibility to such common diseases as cancer and heart disease, may also be inhibited. Thus, as the mapping of the human genome progresses and new genetic tests proliferate, policy makers need to evaluate the legislative and regulatory strategies ro address these concerns.
Toward this goal, this article summarizes and analyzes state legislation on generic information and health insurance. It also highlights the major policy considerations that must be addressed in order to reach consensus on future strategies. This article must be read in context with broader state health insurance reformsS and privacy legislation, as well as important federal legislative and regulatory approaches that affect health insurance and discrimination issues.
The context of insurance 6 Group insurance, individual insurance, self-insurance, and publicly financed insurance (that is, Medicare or Medicjournal of Law, Medicine & Ethics, 23 (1995) : 312-19. © 1995 by the American Society of Law, Medicine & Ethics. 312 aid) represent the primary mechanisms for obtaining health insurance in the United States. Most insureds receive their health insurance through their employer, although over forty million Americans, many of whom are-employed, remain uninsured. 7 Group insurance may be offered to employers based on the company's past claims (experience rating) or, as with Blue Cross/Blue Shield plans, on the average cost of a defined region (community rating). Coverage is also obtained through health maintenance organizations (HMOs) and managed care plans, which may be subject to federal HM 0 regulations on rates, preexisting conditions, underwriting, and other provisions of care.
For small groups and individuals who apply for coverage, commercial insurers underwrite based on personal and family medical history, as well as on risk facrors such as age, occupation, and use of alcohol-and tobacco. Although state insurance laws prevent "unfai-r -discrimination," this provision has nor been interpreted to extend to underwriting based on family and medical history. Furthermore, insurance companies have argued that preventing their access to all medical information will result in adverse selection, by which individuals who know they have a condition, disease, or predisposition to disease may purchase insurance coverage at a premium that will not cover losses.
With increasing frequency, employers provide health insurance benefits through self-funded plans, in which the employer forms its own insurance pool, usually hiring an insurance company to administer its plan. It is estimated that over one-third of the nonelderly insured population throughout this country obtains its coverage through selffunded plans.
1 Self-funded plans providing private health benefits for employees and their dependents ate exempt from state insurance laws pursuant to the Employee Retirement Income Security Act (ERISA) preemption.' Thus, these plans need not follow state laws that require health insurance contractS to include certain benefits, limit preexisting conditions, follow antidiscrimination restrictions, or other state health care reforms.
The increasing use of self-funded plans complicates public policy on genetic information and insurance. Even though the McCarran-Ferguson Act 10 provides that the states have the major regulatory authority for the business of insurance (and so limits any nationwide attempt at insurance reform), ERISA preemption prevents any comprehensive statewide approach to regulating the use of genetic information by all plans providing health benefits. Currendy, no federal legislation addresses genetic information in this context. Furthermore, although the Americans with Disabilities Act of 1990 11 (ADA) protects persons with physical or mental disabilities-including genetic diseases, conditions, and predispositions-from discrimination, 12 Tide V of the ADA provides that, absent "subterfuge," conventional underwriting of risk by commercial insurers or selfinsured employers does not constitute prohibited discrimination. Thus, any comprehensive strategy to regulate genetic discrimination in health insurance must be evaluated in the context of numerous state and federal regulatory issues.
Evolution of state legislation
In the 1970s, a few states began to pass legislation that addressed genetics issues. North Carolina, for example, passed legislation prohibiting health insurers from refusing to issue insurance or from charging higher prerruums based on sickle cell trait or hemoglobin C trait.ll Florida passed similar legislation limited to sickle cell trait.
14 Legislation passed by other states addressed primarily employment, forensics, paternity, and other forms of msurance. Many of these statutes also limited their focus to specific traits and disorders. By 1986, Maryland did pass legislation prohibiting health insurers from rate dJscnminatlon based on "sickle-cell trait, thalassemia-minor tra.Jt, hemoglobin C trait, Tay-Sachs trait, or any genetic tra.Jt wh1ch 1s harmless within itself. " 15 The legislation provided, however, that insurers could continue to use generic inforrTU· cion to discriminate if there was "acruarial justification. " 1 •
Establishing a new framework
By 1991, a new generation of state legislation began to evolve with the passage of a Wisconsin law prohibmng health insurers from:
• requiring or requesting an individual or a member of the individual's family to obtain a genetic test;
• requiring or requesting directly or indirectly into the results of a genetic test;
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• conditioning the provision of insurance coverage or benefits on genetic testing; or
• considering generic testing in determining rates.
This approach attempts to integrate protection against discrimination in insurance practices, coverage, benefits, and rates with some privacy protection for the individual and his/her family. Similar approaches have been incorporated to varying degrees in recent legislation passed in California, 17 Colorado, 18 
Genetic test defined
These recently enacted statutes, summarized in Figure 1 , focus narrowly on the genetic test, rather than on prohibiting discrimination based more broadly on genetic information generated from family history, physical examination, or the medical record. Oregon lawmakers did attempt to address this broader definition, but compromised in prohibiting discrimination based on genetic information that is limited by definition to a genetic test (defined in part as a test of a genetic characteristic) or an individual's DNA sample.
28 California does not define genetic test, rather it prohibits discrimination on the basis of "genetic characteristics," which is defined as "any scientifically or medically identifiable gene or chromosome, or alteration thereof, which is known to be a cause of a disease or disorder, or determined to be associated with a statistically increased risk of development of a disease or disorder, and which is asymptomatic of any disease or disorder. " 29 Regardless of the definition of genetic test, this new generanon of legislation is not focused on a specific genetic tra.Jt or condition, but on a potentially unlimited number of tests. Wisconsin defines a genetic test as a rest using DNA ~extracted from an individual's cells in order to determme the presence of a genetic disease or disorder or the mdividual's predisposition for a particular genetic disease or dtsorder. "
10 In the few years since passage of that law, the deftnition of genetic test has evolved, based in part on advancmg technologies and medical knowledge, and in part on political compromise. Minnesota, for example, defines genetic test as a "presymptomatic test of a person's genes, gene products, or chromosomes for the purpose of determmmg the presence or absence of a gene or genes that exhibit abnormalities, defects, or deficiencies, including earner starus, that are known to be the cause of a disease or disorder, or are determined to be associated with a statistically increased risk of development of a disease or disor- der. " 31 A few states, including California 32 and New Hamp· shire, 33 include reliance on "scientific or medical" accep· ranee of the generic rest within its definition.
Most recently, a Wisconsin bill which has been intro· duced significantly expands the definition of generic test to include "a physical examination of an individual or an examination of the family history of an individual to determine ... whether an individual has a genetic disease or disorder ... or is predisposed ro a generic disease or disorder. "J.< To prohibit discrimination based on prenatal generic testing, "individual" is defined to include an unborn child.JS
Insurance entity defined
It is difficult to define in any general terms the "insurance" entities covered by these statutes, partly because each state defines its jurisdiction pursuant to its own insurance code and regulatory authority. Generally, the Statutes cover health insurance plans, which may be further delineated as hospital service plans, HMOs, third-party administrators, and government entities providing coverage for health care services on a self-insured basis. New Hampshire boldly extends its definition to include self-insurance plans generally,3' even though ERISA is deemed to preempt state in· surance regulation for those plans provided by private employers. This statute also provides, as do most of the other statutes, that life and disability income insurance are not included among the insurance entities prohibited from using generic test results. 37 315 
Privacy protections integrated
Concerns over privacy and genetic information are ad· dressed to varying degrees in many of the statutes. Figures 1 and 2 ) have also adopted this provision. Ironically, the !ecent Wisconsin bill 39 that expands the definition of generic-test, deletes this provision. Proponents of the bill believe that as long as state law prohibits the use of genetic information in the under· writing process, health insurers may have legitimate rea· sons to require or request genetic information. For example, they argue that HMOs, which are both insurers and providers, may need this information to treat the patient and insurers may need access to this information to verify claims. 40 Other states have further expanded on privacy issues. California, for example, prohibits disclosure of genetic test results to any third party without written authorization. 41 Written authorization is required for each separate disclosure of generic rest results and must specify the person or entiry to whom the disclosure will be made. Negligent and willful disclosure without authorization are subject to both civil and criminal liability. Colorado specifically provides that information obtained from genetic testing shall be "con· fidenrial and privileged," 42 and Oregon and Georgia establish that generic information is the "property of the individual. "
43 Nevertheless, they both provide, as do a number of the other states, for specific exceptions in which written authorization is not required for disclosure (that is, paternity, criminal proceedings, or health department protocols). Even when these statutes require informed consent prior to genetic testing, they do not address whether the informed consent process will incorporate a warning that the test results may be disclosed without authorization under certain circumstances.
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A Florida law passed in 1992 also permits DNA analysis to be used 'Nithour informed consent in criminal prosecu· tions, other criminal matters, and paternity determinations."" Except in these circumstances, the Statute declares that the test results are the exclusive property of the person tested, are confidential, and may not be disclosed without consent. Nevertheless, the statute does not prohibit the use of genetic information in determining health insurance coverage and benefits. If DNA test results are used in any decision to grant or deny insurance, the individual must be notified, and the analysis must be repeated to verify its accuracy. 
Study groups established
Over the last few years, a number of states, most recently Nebraska,S 1 Ohio,n and Vtrginia, 53 have passed legislation . , .. to. establish task forces or commissions to study the policy and societal issues raised by genetic information. The state of Virginia specifically provides for a subcommittee to study the l~al and policy ramifications of breast cancer susceptibility· gene research, including the ethical and legal issues of health insurance coverage and reimbursement.
Other legislative experiences
Recently, a number of other states have attempted to pass without success legislation addressing generic discrimination and health. Proposals often failed because of splits along political party lines. In Texas/' the genetic discrimination and insurance bill failed in committee despite a compromise that would have removed disability income and life insurance. When the bill was put to a committee vote, two liberal members refused to support the bill because it was limited only to health insurance. In fact, in a number of the states that have enacted legislation, bills were passed only after life and/or disability income insurance were excluded. New York State has attempted legislation to address health insurance issues as part of a comprehensive omnibus bill addressing numerous generic discrimination issues. ss This approach has not achieved support, and the legislature is now considering ocher bills limited to one issue at a rime (that is, employmenrl 6 or privacf?). In other states, legislators have indicated that there is a lack of understanding and legislative apathy concerning the issue of genetic discrimination.
Policy considerations
The development of public policy to address generic information and health insurance must be analyzed in light of a complex and inadequate health insurance system, the uncertainty about the future scope and impact of generic testing, and the political realities of a pluralistic society. The current patchwork of state legislative approaches does not provide a comprehensive solution to genetic discrimination and health insurance. State laws focus narrowly on genetic tests, rather than broadly on genetic information generated by family history, physical examination, or the medical record. Although health insurers are prohibited from using the results of a chemical test of DNA, or the protein product of a gene, they can still use other phenotype indicators, patterns of inheritance of genetic characteristics, or requests for genetic testing as the basis for discrimination. 58 Thus, "meaningful protection against generic discrimination requires that insurers be prohibited from using all information about genes, gene products, or inherited characteristics to deny or limit health insurance coverage. " 59 Second, a large proportion of the population receives its health benefits from self-insured plans not subject to State insurance laws. The ERISA preemption prevents a statewide approach to regulating the use of genetic information by all plans providing health benefits. Furthermore, no federal laws specifically address genetic discrimination in health insurance.
Recent health insurance proposals at both the state and federal level focus primarily on modest reform in the areas of accessibility, portability, and renewability of coverage, prohibiting insurers from denying coverage based on health Status or medical condition, but often permitting exclusions for preexisting conditions for limited time periods. It is unclear whether and to what extent genetic information would be covered by these proposals. 60 For example, unlike medical conditions, generic information may provide insight into an individual's and/or family member's predisposition to future disease. 61 With these policy considerations in mind, the followmg recommendations were developed by the Working Group on Ethical, Legal, and Social Implications of the Human Genome Project (ELSI) 62 and the National Action Plan on Breast Cancer (NA.PBC)'J as guidelines for both state and federal policy makers to protect against genetic discrimination:
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(1) Insurance providers should be prohibited from using genetic information, or an individual's request for genetic services, to deny or limit any coverage or to eStablish eligibility, continuation, enrollment, or contribution requirements.
(2) Insurance providers should be prohibited from establishing differential rates or premium payments The recommendations further provide that genetic information be defined as "information about genes, gene products, or inherited characteristics that may derive from the individual or a family member. "
65 Insurance provider is defined as "an insurance company, employer, or any other entity providing a plan of health insurance or health benefits including group and individual health plans whether fully insured or self-funded.""
These recommendations evolved, in part, from a critical analysis of State legislative approaches. nus analytical framework is intended to stimulate a comprehensive solution to geneti~-~scrimination in health insurance 117 that integrates bach privacy protection and the reality that genetic information is much more than jusr a test result.
